SK pharmteco’s Post

Have you read our recently released target product profile (TPP) guide and want to learn more about how to develop an effective TPP for successful therapy adoption? Join our webinar on the 31st of January titled 'Developing a robust target product profile (TPP) for successful therapy adoption', where Cell and Gene Therapy Catapult’s experts in #MarketAccess, #RegulatoryAffairs and #NonClinical strategy will talk through the guide, discuss the value of a TPP and how to approach building one. Register now: https://buff.ly/3RqT2nC #TargetProductProfile #CellTherapies #GeneTherapies #TherapyDevelopers

What will it take for gene therapies to achieve commercial success that matches their clinical potential? Read on as my colleagues address some of the key challenges. #cgt #genetherapy #celltherapy #cellandgenetherapy

Our CGT team synthesized our thoughts on the current state of gene therapies and where we are heading in this recent blog post!

Headed to ASGCT this week? Stop by Booth #2235 to learn about our extensive commercial experience and regulatory track record to help advance your gene therapy to patients with more certainty. #ASGCT2024

ICYMI: Listen to Dr. Salvador Rico, CMO of Encoded Therapeutics Inc., discuss the company's gene therapy and overall program looking to tackle #DravetSyndrome https://lnkd.in/eZkjigEh #InternationalEpilepsyDay Dravet Syndrome Foundation

There are many obstacles with managing the ancillary materials used in the production of cell and gene therapy products. In this webinar, sponsored by BioLegend, we discover the critical qualities of cytokines, growth factors, antibodies and culture media and risk-based strategies for assessing these challenges. Register now >>> https://hubs.ly/Q02HD5hk0

2024 is shaping up to be a transitional period for the #biopharma industry, as the market eyes a return to growth in the wake of a post-pandemic contraction. Gene therapies remain at the forefront of this transition, with recent approvals and upcoming milestones placing a spotlight on the sector.   Despite demonstrating impressive scientific innovations, gene therapies have often fallen short of commercial expectations, and more recently #investors have been hesitant to back the modality.   In our latest blog, we discuss the #genetherapy outlook for 2024 and beyond, and we take a closer look at what events might serve as catalysts for the sector’s anticipated breakout. Read here: https://bit.ly/3wCCAtr Vivek Mittal, Ned Wydysh, Tom Fitzsimons

Discover how QPS Holdings, LLC’s Leukopak facility can pave a quicker path to the clinic for cell and gene therapies in this interview with Study Director, Polung Yang! Delve into the recent innovations in the field and how these services can accelerate therapeutic manufacturing >>> https://bit.ly/3V7gW9m

AAV Analytics: Key Considerations When Developing a Clinical Program https://lnkd.in/e5E_bu5a Finding capable partners with the requisite expertise to optimize AAV processes is important for reducing variability and risk. Please join Andelyn for this webinar in which we will discuss key considerations for taking your AAV gene therapy from concept to commercialization with advanced analytics. 

Advancing cell and gene therapies (CGTs) globally presents unique hurdles at every step, and Labcorp has the experience and capabilities to help you overcome them. In a recent presentation for the Korea Biomedicine Industry Association (KoBIA), Maryland Rosenfeld Franklin, PhD, vice president and enterprise head of CGT at Labcorp, discussed some of these challenges and explored their solutions. Watch the recorded webinar to learn more. #CellandGeneTherapy #CellTherapy #GeneTherapy